AUCKLAND, New Zealand and LONDON and SAN FRANCISCO, Jan. 11, 2016 /PRNewswire/ -- Atlantis Healthcare Group Limited ("AH"), a global leader in digital patient adherence and self-management solutions, announces today the appointment of Matthew Walls as Executive Chairman and CEO of AH, coinciding with the Company's presence at the 34th Annual JP Morgan Healthcare Conference in San Francisco. Mr. Walls brings a 30 year background in healthcare, medical devices and technology, therapeutics and innovation investment to AH set against a broad international experience of life science, pharmaceutical, and communications-based businesses.
"My goal is to ensure the establishment of AH and its products as international leaders in treatment adherence and patient self-management," said Mr. Walls. "Our focus remains to strengthen and support the international rollout of our core products and technology around our clinically-proven programs and models to drive behavioral change on an international scale through personalized interventions or as we like to refer to it, mass personalization."
Mr. Walls also serves as a Senior Adviser to White Cloud Capital, the private family strategic investment company that is the principal investor in AH. Prior to AH, Mr. Walls was CEO of Epistem Holdings Plc, leadings its admission to the UK Stock Exchange with responsibility for driving the development of the Company to become global leaders in epithelial stem cell science, personalized medicine and Point of Care (POC) diagnostics.
Mr. Walls has a strong track record for identifying and nurturing rapidly growing technology companies, raising new investment and delivering significant investment returns. Prior positions include CEO of OBS Inc, developers of proprietary signal technology for biometric applications in healthcare and industrial markets, and CEO of Internexus Group/Supanet, providers of internet and e-business solutions ranked within the top 5 ISP providers in the UK. Prior to this Mr. Walls spent the major part of his early career with AstraZeneca Plc where he occupied several senior roles including Commercial Director for Biotechnology.
"Atlantis Healthcare has successfully grown its patient adherence solutions enjoying rapid growth across its global pharma client base and its nascent public healthcare platform. I look forward to building on this progress and to guiding Atlantis through its next phase of development," said Mr. Walls. "The next phase includes partnering our products and technology on an international basis with healthcare providers, public health and health insurers to develop and deliver personalized behavior change solutions to empower patients to self-manage their treatment and improve health outcomes."
For more information, visit www.atlantishealthcare.com
About Atlantis Healthcare Group
For over 20 years, AH has designed and implemented personalized patient support solutions that drive sustained therapeutic adherence through self management helping to improve patient outcomes. The group provides its products and services on an international basis from offices in Australia, Germany, New Zealand, Spain, UK and the USA. It has run over 140+ patient programs in more than 50 disease states, addressing over 1 million patients in 20 countries. The disease states addressed range from mass non-communicable diseases such as Asthma, Cardiovascular and Diabetes through to rare diseases.
AH specializes in 'self-management' program design and implementation leading to improved patient behaviors and reduced cost set against the 'patient journey' and a structured approach to supporting and monitoring therapeutic treatment. AH single longest running patient support program has been in place for 8 years in breast cancer.
AH has the largest team of globally recognized health psychology experts in a commercial setting from which the company leverages its clinically-proven models and academic research to develop award-winning international behavior change and self-management programs to improve patient outcomes.
SOURCE Atlantis Healthcare